Calgary, Alberta, August 1, 2024 – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it and CytoImmune Therapuetics (“CytoImmune”) today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01
Latest news and articles!
Calgary, Alberta, June 11, 2024 – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by
Calgary, Alberta, June 3, 2024 – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it has signed a Letter of Intent (“LOI”) with CytoImmune Therapuetics (“CytoImmune”) to re-establish production of ACP-01 (“ACP”) in CytoImmune’s
Calgary, Alberta, March 7, 2024, 2024 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (“OHAM”), an Exempt Market
Calgary, Alberta, February 6, 2024 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company’s Phase II randomized
Calgary, Alberta, December 29, 2023 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to clarify its press release of October 3, 2023. It refered to the private placement of
Calgary, Alberta, October 23, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it has amended its $2.5 million 5 year convertible debenture, which originally closed on June 11, 2021 (“CD1”) resulting in
Calgary, Alberta, October 3, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce it closed its private placement of $320,125, the sale of approximately 2.66 Million Units priced at $0.12 each. Each Unit
Calgary, Alberta, September 28, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce a new private placement of $325,125, the sale of approximately 2.7 Million Units priced at $0.12 each. Each Unit shall
Calgary, Alberta, September 12, 2023: – Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0) is pleased to announce its study of NCP-01 supporting brain computer interfaces has been submitted for peer review publication. Mitigating Challenges Facing Clinical Applications